menu

LDH and Evolving Treatment Success?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Forging New Paths Ahead: Challenging the Current Standard of Care for PNH

LDH and Evolving Treatment Success?

Minute CME/CE™
ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.75 credits
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Episodes
Presenters
Documents
Comments
  • Overview

    This program provides awareness of current challenges in the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The emergence of newer therapeutic approaches leads to the creation of new opportunities to improve patient care and establish treatment goals. A greater understanding of new mechanistic actions may directly impact patient QoL. Clinicians, especially among hematologists and advanced care nurses, may lack confidence in their ability to fully treat patients with PNH due to inadequate control of anemia which is often overlooked due to a greater priority in measuring lactate dehydrogenase (LDH). In turn, by increasing awareness of the latest and emerging data surrounding the C3 pathway, its clinically meaningful impact on controlling PNH, and associated impact on efficacy and safety, hematologists and advanced care nurses can become more comfortable integrating new therapies into practice. These agents are likely to have a significant impact and fill an unmet need in the treatment of PNH and ultimately improve patient QoL.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team involved in the management of patients with PNH. This includes, but is not limited to, hematologists/oncologists, physicians, nurses, pharmacists, and other members of the interprofessional team who are involved in the management of patients with PNH.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    1. Illustrate the pathophysiology of PNH and understand the consequences of the disease
    2. Describe the prevalence and unmet patient needs associated with PNH
    3. Explain the clinical markers of success in the management of PNH and their associated value
    4. Interpret the guidelines, while applying and differentiating the safety profiles of current and emerging therapeutics for PNH
    5. Understand emerging data of classes and mechanisms of drugs, with a focus on EVH, IVH, anemia, and compliance of pharmacological treatments in controlling PNH
  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 2.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    The following faculty has reported relationships with ineligible companies:

    Catherine Broome, MD, faculty for this educational event receives research funds for Annexon, Argenex, Sanofi, Rigel Pharmaceuticals, and Incyte; and receives consulting fees from Alexion, Apellis, Sanofi, Argenx.

    Carlos M. de Castro, MD, faculty for this educataional event receives consulting fees from Alexion, Apellis, Novartis, Biocryst, and Regeneron.

    Bhumika Patel, MD, faculty for this educational event receives consulting fees from Alexion, Apellis, and Novartis.

    Ilene C. Weitz, MD, faculty for this educational event receives consulting fees from Alexion, Apellis, and Biocryst. 

  • Planners and Managers Disclosure List

    The following reviewers/planners have reported no relationships with ineligible companies:

    Robert Garris, PharmD, MPH, planner for this educational event, has no relevant financial relationships with ineligible companies.

    William Mencia, MD, FACEHP, CHCP, planner for this educational event, has no relevant financial relationships with ineligible companies.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by an independent educational grant from Apellis Pharmaceuticals, Inc.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions for Completion

    During the period 8/12/2022 through 8/12/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:

    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Customize your experience based on your profession
Profession
Registration is a short process and your information will be kept safe.
Schedule7 Dec 2022